Background/Aim. After introduction of carefull selection procedure for blood donors and the implemention of highly sensitive screening tests for transfusion transmissible infections (TTI), blood is very save product concerning TTI. Nevertheless, because of the ?window? period for the pathogen that are testing and the emergence of new pathogens, the risk stil persists. Implementation of pathogen reduction technology (PRT) provides a proactive approach to improve blood safety. By damaging nucleic acids, PRT selectively inactivates pathogens and leucocytes. However, during the process, plasma proteins are, also, damaged in some extent. The goal of this study is to conclude if there is the difference in the effect of PRT on Protein S and ?2-antiplasmin regarding the time of inactivation: inactivation immediately after plasma separation from whole blood (before freezing) versus inactivation after freezing/thawing. Methods. The voluntary donors' blood is taken into quadruple bag system, centrifuged and separated into blood products. Control's group plasma is inactivated by the Mirasol PRT system and frozen. Experimental's group plasma is frozen and, after four months, thawed and inactivated. Protein S and ?2-antiplasmin activity are examined in samples after separation, inactivation and thawing. Results. Analysing Protein S and ?2-antiplasmin activity, no statistically significant difference is found between the initial samples. The trend of reduction of protein's activity after inactivation and freezing/thawing is present in both groups but without statistically significant intergroup difference. Conclusion. Reduction in Protein S and ?2-antiplasmin's activity after immediate - before freezing and afterwards - after freezing/thawing inactivation does not show a statistically significant difference, making stored plasma unites suitable for safe and efficient inactivation directly before clinical use and according to patient's blood type.
Introduction. SARS-CoV2 2019 infection represent global problem. At this moment there is no vaccine or efficient treatment of infected patients. Treatment with blood plasma rich with anti SARS-CoV2 specific antibodies represents rare safe and effective treatment of Covid19 patients. Patients and Material. A total number of 950 patients were analyzed in this study, whose samples were collected in time interval from 01.05. till 15.08.2020. Patients were enrolled in study from Covid-19 hospitals, out-clinics and as family members of SARS-CoV2 infected patients. Original ELISA tests were developed to measure the concentration of anti-S1S2 Spike and anti-Nucleoprotein (IgG, IgA, IgM) SARS-CoV2 antibodies. Blood convalescent plasma was selectively collected from recovered patients according to specific antibodies concentration. Results. The highest concentrations of anti-S1S2 Spike or anti-Nucleoprotein specific IgG antibodies were detected in patients with the moderate/heavy clinical form of infection as well as in group of family members of SARS-CoV2 infected patients. Extremely high concentration of anti S1S2 Spike IgG and anti-Nucleoprotein IgG was demonstrated in 3% and 6% (respectively) of patients recovered from severe Covid19. From our hospitalized patients 63% and 51% had modest antibody levels (anti S1S2 Spike and anti-Nucleoprotein, respectively). After 60 days, in our selected donors? concentration of anti S1S2 Spike IgG antibodies increased in 67%, paralleled with increase of anti-Nucleoprotein IgG antibodies in 58% of donors. Conclusion. Originally developed ELISA tests enable novel protocol for selection of convalescent blood plasma donor.
Despite numerous measures, bacterial sepsis associated with the transfusion remains a major threat. The incidence of septic events induced by platelets transfusion is approximately 10 times higher than with transfused red blood cells due to their storage temperature. This caused new Standard that implements the methods for the detection and reduction of bacteria in the platelet concentrates (PC). The aim is to consider the possibility of wider application of this tests in order to extend the shelf-life of PC. Sterility testing of PC is done once or twice per month using BacT/Alert BPA and BacT/Alert BPN bottles. If positive, all products from the initial unit were tested to confirm or deny the status. During six years period, 67236 PC units were made and 872 of them were tested. Only two were found initially positive. After testing the other products from the same initial unit, results were negative so, final results proclaimed false positive. Pretransfusion bacterial detection is an important potential method for reducing the risk of bacteriemia and transfusion-associated septic reactions. In addition to routine measures, Mirasol PRT pathogen inactivation system, could be included. This allows certain amount of PC to be inactivated during the first 32 hours. Untreated PC units would be stored in standard conditions and for given time (three days) potentially present bacteria would reach a detectable level. This way the quantity of samples for sterility testing could be reduced, taking only 2 mL of each of four units of PC. Samples would be planted at the same vial-aerobic bottle, which would also, double the capacity in BacT/Alert 3D automated system.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.